3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
28
Melanoma
9
Triple Negative Breast Neoplasms
8
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Colorectal Neoplasms
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Sarcoma
3
Ovarian Neoplasms
3
Neoplasms
3
Mesothelioma
3
Lymphoma
3
Head and Neck Neoplasms
3
Adenocarcinoma of Lung
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
NSCLC
2
Liver Neoplasms
2
Kidney Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Interventions
pembrolizumab
9
Carboplatin
9
Docetaxel
8
Paclitaxel
6
Nivolumab
6
Cisplatin
5
Gemcitabine
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
osimertinib
3
fludarabine
3
aldesleukin
3
Radiotherapy
3
Pemetrexed
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
motexafin gadolinium
2
figitumumab
2
cemiplimab
2
brigatinib
2
atezolizumab
2
alpha-2'-deoxythioguanosine
2
Taxes
2
Radiosurgery
2
Ipilimumab
2
Interleukin-2
2
Crizotinib
2
Bevacizumab
2
vistusertib
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
spartalizumab
×
Thoracic
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts